Workload measurement for molecular genetics laboratory: A survey study by Tagliafico, Enrico et al.
RESEARCH ARTICLE
Workload measurement for molecular
genetics laboratory: A survey study
Enrico Tagliafico1,2*, Isabella Bernardis1,2, Marina Grasso3, Maria Rosaria D’Apice4,
Cristina Lapucci5, Annalisa Botta6, Daniela Francesca Giachino7,8, Maria Marinelli9,
Paola Primignani10, Silvia Russo11, Ilaria Sani12, Manuela Seia13, Sergio Fini14,
Paola Rimessi14, Elena Tenedini1,2, Anna Ravani14, Maurizio Genuardi15,
Alessandra FerliniID14*, on behalf of the Molecular Genetics Working Group of the Italian
Society of Human Genetics, SIGU¶
1 Center for Genome Research, University of Modena and Reggio Emilia, Modena, Italy, 2 Department of
Medical and Surgical Sciences, University of Modena ad Reggio Emilia, Modena, Italy, 3 Laboratory of
Human Genetics, Galliera Hospital, Genoa, Italy, 4 Medical Genetics Laboratory, Tor Vergata Hospital,
Rome, Italy, 5 Medical Genetics and Molecular Biology Unit, Synlab Italy, Brescia, Italy, 6 Dept. Biomedicine
and Prevention, Medical Genetics Section, Tor Vergata University of Rome, Rome, Italy, 7 Medical Genetics,
University of Torino, Dept. Clinical &Biological Sciences, Torino, Italy, 8 Medical Genetics, San Luigi
University Hospital, Orbassano, Italy, 9 Genetics Laboratory Unit, Department of Obstetrics and Pediatrics,
AUSL-IRCCS of Reggio Emilia, Reggio Emilia, Italy, 10 Department of Laboratory Medicine, Medical
Genetics, Niguarda Ca’ Granda Hospital, Milan, Italy, 11 Cytogenetics and Molecular Genetics Laboratory,
Istituto Auxologico Italiano, I.R.C.C.S., Milan, Italy, 12 Genetica Medica—AOU "A. Meyer" di Firenze,
Florence, Italy, 13 Medical Genetics Laboratory; Fondazione IRCCS Ca’ Granda Ospedale Maggiore
Policlinico, Milan, Italy, 14 Unit of Medical Genetics Unit, Department of Medical Sciences, University of
Ferrara, Ferrara, Italy, 15 Istituto di Medicina Genomica, Università Cattolica Del Sacro Cuore, Fondazione
Policlinico Universitario A. Gemelli, Rome, Italy
¶ The complete membership of the Molecular Genetics Working Group of the Italian Society of Human
Genetics, SIGU can be found in the Acknowledgments section.
* fla@unife.it (AF); enrico.tagliafico@unimore.it(ET)
Abstract
Genetic testing availability in the health care system is rapidly increasing, along with the dif-
fusion of next-generation sequencing (NGS) into diagnostics. These issues make impera-
tive the knowledge-drive optimization of testing in the clinical setting. Time estimations of
wet laboratory procedure in Italian molecular laboratories offering genetic diagnosis were
evaluated to provide data suitable to adjust efficiency and optimize health policies and
costs. A survey was undertaken by the Italian Society of Human Genetics (SIGU). Forty-two
laboratories participated. For most molecular techniques, the most time-consuming steps
are those requiring an intensive manual intervention or in which the human bias can affect
the global process time-performances. For NGS, for which the study surveyed also the inter-
pretation time, the latter represented the step that requiring longer times. We report the first
survey describing the hands-on times requested for different molecular diagnostics proce-
dures, including NGS. The analysis of this survey suggests the need of some improvements
to optimize some analytical processes, such as the implementation of laboratory information
management systems to minimize manual procedures in pre-analytical steps which may
affect accuracy that represents the major challenge to be faced in the future setting of
molecular genetics laboratory.
PLOS ONE | https://doi.org/10.1371/journal.pone.0206855 November 27, 2018 1 / 13
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Tagliafico E, Bernardis I, Grasso M,
D’Apice MR, Lapucci C, Botta A, et al. (2018)
Workload measurement for molecular genetics
laboratory: A survey study. PLoS ONE 13(11):
e0206855. https://doi.org/10.1371/journal.
pone.0206855
Editor: Alvaro Galli, CNR, ITALY
Received: May 11, 2018
Accepted: October 19, 2018
Published: November 27, 2018
Copyright: © 2018 Tagliafico et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Funding was provided by Programma di
ricerca Regione-Università "Next-generation
sequencing and gene therapy to diagnose and cure
rare diseases in Regione Emilia Romagna
(RARER)" - Area1, Strategic Programmes (grant
number E35E09000880002) to AF. Synlab Italy
provided support in the form of salaries for author
CL, but did not have any additional role in the study
design, data collection and analysis, decision to
Introduction
New technologies in genomics are changing clinical practice, increasing the volume of genetic
testing and, consequently, healthcare spending. Besides, the evolution of knowledge in geno-
mics and in medical genetics has also elicited the need for accurate estimation of the cost
impact of genetic testing on healthcare system in relation to clinical utility. In fact, with the
rapid diffusion of next-generation DNA sequencing technologies into diagnostics, and the dra-
matic drop down of the cost of sequencing, genomics has started to pervade health care in the
area of traditional genetic diseases as well as across the entire medical field, from preconcep-
tion to aging.
Therefore, detailed knowledge of genetic testing costs, are mandatory to design efficient
and optimized health policies in the near future.
Estimates of laboratory workload have been reported for some laboratory specialties,
including microbiology [1], pathology and laboratory medicine [2]. Several documents on
both clinical and laboratory workloads are present on the web (https://www.cap-acp.org/
wkload.php).
In the medical genetics field, estimates have been undertaken for genetic counselling activi-
ties and cytogenetic diagnosis [3]. A time analysis of clinical workload linked to molecular
genetic testing has been performed more than 20 years ago [4]. Sixteen Canadian genetic ser-
vices were surveyed, and the following median times were calculated: 60 minutes for standard
counselling, 15 minutes for follow up face to face consultation (case review), 10 minutes for a
phone discussion, and 15 minutes each for letter, intermediate report and specimen set up.
Molecular test interpretation was 10 minutes. Times were highly variable, depending on dis-
ease inheritance and on the number of clinical actions required.
More recently, Heald et al.[5] proposed that workload might be better articulated depend-
ing on the type of clinical service offered. They therefore calculated workload for general coun-
selling, as well as for counselling related to cancer, cardiovascular, and prenatal genetic
activities. They also concluded that non-clinical activities should be transferred to supporting
staff (hospital technicians, nurses). Great variety in time measurements was observed for mini-
mum total time spent, first or second counseling sessions, and general versus specific
counselling.
Obviously, workload measurements are helpful if not necessary for predicting clinical
resources, hospital staffing and personnel enrollment.
Molecular laboratory workload was briefly considered by Susan Steinhouse (https://ukgtn.
nhs.uk/fileadmin/_migrated/tt_news/news_files/RCPath_article_MolUs.pdf), who described
and commented on the UK National External Quality Assessment Service (NEQAS) for
Molecular Genetics activities. Participating laboratories were asked to assign workload to the
EQA cases. The output of this study showed significant differences across laboratories. “Work-
load units”, equating to one minute of laboratory work, were used for the measurements. This
approach might be rather complex when many techniques (DNA extraction, PCR, sequencing,
MLPA, genotyping, also counting the number of amplicons) are monitored.
The Italian Society of Human Genetics (SIGU) has a robust experience in collecting data
and activities of the Italian Medical Genetic Services in order to describe the Medical Genetics
national scenario. The last survey of medical genetic services in Italy was reported by Giardino
et al. providing an overview of the activities over a 4-year period [6].
We surveyed the time workload related to the laboratory techniques routinely used for
molecular testing including next generation sequencing (NGS). In particular, this is the first
study providing this type of information for NGS procedures. The purpose was to provide
time estimates of wet laboratory procedures in Italian molecular laboratories offering genetic
Laboratory hands-on-time in molecular diagnostics
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diagnosis. Here we show the results, interpretation and considerations derived from this sur-
vey, highlighting the importance, specificity and peculiarity of diagnostic-oriented molecular
laboratory activity and underlying how to improve genetic testing productivity, in line with
the current requirements of public health.
Materials and methods
A survey was launched by the Molecular Genetics Working Group via the Italian Society of
Human Genetics (SIGU). The survey was addressed to all members affiliated with SIGU society.
No specific criteria were applied for laboratory selection. Two different questionnaires were pre-
pared: Survey A, containing 55 questions, was designed to gather information about workloads
and hands-on times for standard basic molecular techniques, while survey B, including 41 ques-
tions, was focused on Next-Generation Sequencing (NGS). A total of 42 laboratories partici-
pated in survey A, while survey B was restricted to 18 laboratories performing NGS analyses.
Data collected included number and type of processed analyses with average hands-on
times for different ranges of sample size workloads. Workload was examined for all molecular
genetics procedures performed nationwide to diagnose genetic diseases. The following tech-
niques were surveyed considering the hands-on-time for the manual procedures, even if
requested by automated protocols: Nucleic Acid Extraction, PCR, Reverse dot blot, Multiplex
Ligation-dependent Probe Amplification (MLPA), Sanger sequencing, NGS sequencing (gene
panels and exomes). For these techniques hands-on-time for each step of the analysis protocol
were considered and evaluated.
Data from responding laboratories were collected and analyzed using R statistical package
(matrixStats, doBy, ggplot2). For each question, the analyses were performed only if responses
were available from a minimum of two laboratories. Time-per-sample calculations were per-
formed considering different ranges of sample size workflows, and an average sample size
workflow was estimated. Extreme outlier time values (lower/upper quartile ±3�IQ; IQ: inter-
quartile range) were discarded from statistical analysis.
This study did not require any ethical approval, since no human subjects or human biologi-
cal material were used, and only the techniques and laboratory methods were analyzed. Conse-
quently no informed consent from patients was taken within the study. All original material is
supplied and can be downloaded as supplementary files: Survey modules: SURVEY A module
English (S1 Survey), SURVEY A module original language (S2 Survey), SURVEY B module
original language (S3 Survey) along with a translated copy of guidelines to complete survey (S1
File), and Survey raw data: SURVEY A Raw Data (S4 Survey), SURVEY B module and Raw
Data English (S5 Survey)
Results
The number of laboratories that returned questionnaires for Survey A and Survey B are 39 and
18, respectively. Among the laboratories that answered Survey A, 67% (n = 26) reported using
NGS, 57.6% of which (n = 15) filled-out also Survey B. Three laboratories returned Survey B
only. Overall, response was obtained from 42 different laboratories (24 Survey A, 15 Survey A
and B, 3 Survey B). Considering the geographic distribution of responding laboratories, North
and Central Italy are the most represented regions, with a north-to-south decreasing gradient
already observed in previous studies [6]: 57.1% and 28.6% of laboratories are located in the
Northern and Central regions, respectively, compared to 14.3% in the Southern regions. Of
the 42 responding laboratories, 31% are affiliated with university hospitals, 31% with public
(16.7%) or private (14.3%) research hospitals, 14.3% with public hospitals and 11.9% with uni-
versities. Private laboratories accounted for the remaining 7.1%.
Laboratory hands-on-time in molecular diagnostics
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All responding laboratories reported information for each molecular activity. Fig 1 shows
the fractions of labs performing each activity.
The summary of results of the data analysis of hands on times for the different molecular
techniques considering an average workload are shown in Fig 2 and in Table 1. Sample DNA
extraction analyses showed the greatest hands-on times, with also the greatest variation across
laboratories for manual extraction (range 3–55 minutes/sample), suggesting, when compared
with semi-automated and automated extraction (range 4–27 and 2–35 respectively) that these
Fig 1. Fractions of labs performing each molecular procedure. Number (out of total) and percentage of labs performing
each analytical procedure and who have completed the corresponding questionnaire sheets.
https://doi.org/10.1371/journal.pone.0206855.g001
Fig 2. Hands-on times for each molecular procedure. Hands-on times for the molecular techniques surveyed. An average sample workload is considered. In box plots,
center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by R software; whiskers extend 1.5 times the interquartile range from the
25th and 75th percentiles, outliers are represented by dots. With regard to DNA extraction, "manual" refers to a basic technique that does not use kits and/or automation
(e.g. Phenol-Chloroform); "semi-automated" refers to protocols in which commercial DNA extraction kits are used with simplified workflows, but no pipetting
automation equipment is used; "automated" refers to a fully automated protocols implemented on liquid handlers platforms (e.g. Promega Maxwell, Qiagen
QIASymphony etc.).
https://doi.org/10.1371/journal.pone.0206855.g002
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analyses are heavily operator- and method-dependent (differences in extraction methods have
not been taken into account for hands-on times measurements).
As expected, for all procedures hands-on times per sample decreased with increasing sam-
ple size (S1 Fig) [7].
Interestingly, when analytical steps were considered, for the large majority of molecular
techniques, the most time-consuming steps are those that require an intensive manual inter-
vention or in which the human bias can affect the yield in terms of time such as the pre-analyt-
ical phase, the preparation of daily worksheets and the reaction setup of the analytical session
(Fig 3).
With regard to NGS, the responding laboratories reported workloads ranging between 20
and 300 samples/month (mean 90.05, median 55, SD 89.10). 66.6% of laboratories use an Illu-
mina platform (Illumina Inc., San Diego, CA, USA (41%of them have both MiSeq and Next-
Seq/HiSeq) while 33.3% an Ion Torrent platform (Thermo Fisher Scientific Inc. Waltham, MA
USA); 11% of laboratories use both Illumina and Ion Torrent platforms.
Fig 4 shows the distribution of amplicon-based and capture-based strategies for target
enrichment according to gene panel size. Overall, the amplicon-based technology is preferred
to capture, mainly for small gene panels. Automated workflows were used by only one labora-
tory and 1/3 of the laboratories for capture-based target and amplicon-based target enrich-
ment, respectively (data not shown).
The results of the data analysis of hands-on times for NGS are reported in Fig 5. Panel A
and B show the hands-on times for amplicon- and capture-based technologies, respectively.
As expected, the most time-consuming step in the NGS analysis workflow is test interpreta-
tion. The time increases with the number of genes tested with an average of 1.6 hours
requested for analyzing panels of 2–10 genes, 1.9 hours for 11–40 genes, 2.8 hours for 41–200
genes, and 6 hours for exomes (Fig 5C).
With regard to NGS data analysis pipelines, for small gene panels, the majority of laborato-
ries use the software provided by the NGS platform, or in-house pipelines, whereas 30% use
commercial software; for large panels and exomes, the implementation of in-house pipelines
becomes predominant (80–100%). For data interpretation, in-house pipelines are the most
used for intermediate gene panels (70–80%), whereas the use of commercial software increases
with panel size (up to 50%), reflecting the need of additional tools for the interpretation of
more complex and bigger amounts of data.
Table 1. Hands-on times for each molecular procedure. Hands-on times for the different molecular techniques con-
sidering an average.
Median
(minutes)
Mean
(minutes)
SD
Manual Extraction 17,85 19,88 11,2
Semi-automated Extraction 7,88 11,67 13,21
Automated Extraction 6 10,91 9,91
MLPA 6,4 6,5 2,3
MS-MLPA 9,1 9,48 3,45
PCR 4,05 5,97 6,51
PCR Fragment Analysis 6,67 7,85 5,99
PCR Dynamic Mutations 5 6,7 4,54
RDB 5,99 9,03 7,63
Sanger 5,7 9,66 11,16
Hands-on times for the molecular techniques surveyed. Median, Mean and Standard deviation are reported.
https://doi.org/10.1371/journal.pone.0206855.t001
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Discussion
Molecular genetic diagnostic testing has become increasingly sophisticated during the last few
years, mainly due to the breakthrough of genome and exome sequencing technologies. These
play an increasingly important role in for highly penetrant diseases and cancer, allowing faster
and more precise diagnosis, carrier testing of inherited disorders, family planning, and choice
and monitoring of personalized therapies. Therefore, molecular genetic testing and clinical
genomics represents one of the most powerful instruments in the personalized medicine era
[8]. At the same time, molecular genetic laboratories must ensure high quality performances
Fig 3. Hands-on times for each step of molecular procedure. Hands-on times for the different analytical steps of the molecular techniques surveyed. An average
sample workload is considered. In box plots, center lines show the medians; box limits indicate the 25th and 75th percentiles as determined by R software; whiskers
extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots.
https://doi.org/10.1371/journal.pone.0206855.g003
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taking into account health-care provider requirements and patient management, numbers and
types of biological samples, key challenges for each genetic/genomic technology, reporting
turnaround times, optimization of working conditions for laboratory, and post-testing patient
caring medical teams.
Management-engineering methods have been successfully applied to healthcare domains,
such as clinical chemistry laboratories or clinical units/departments, using process design
models to impact on those contexts. So far, these approaches have not been systematically
applied to molecular genetics or clinical genomics laboratories. Therefore, there is a need to
understand the peculiarities of the molecular genetics laboratories and the kind of tools and
best practices that could be applied to improve this setting.
In order to fill in these gaps, we have undertaken the first survey describing the times
requested for different molecular diagnostics procedures. The results obtained provide the
grounds for an in-depth analysis of the operational workflows of molecular genetics
laboratories.
Molecular genetics diagnostic testing is the translational output of research procedures and,
even if it has become increasingly sophisticated, it has not yet reached the process optimization
standards that are specific of high throughput laboratories, such as clinical chemistry laborato-
ries. This survey allows some considerations that might be useful to optimize some analytical
processes.
Our data strongly suggest that, for the large majority of molecular techniques, the highly
time-demanding operations are those that require greater manual intervention or in which the
human bias can affect the global process time-performances such as pre-analytical steps, and
setup of the analytical sessions. For all laboratory procedures, the pre-analytical phase is cur-
rently considered as the weakest part of the testing process because of its effect on the global
quality of the final results.
Fig 4. NGS strategies for target enrichment. Percentage of laboratory adopting the different strategies for target enrichment
according to gene panel size.
https://doi.org/10.1371/journal.pone.0206855.g004
Laboratory hands-on-time in molecular diagnostics
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Moreover, the analysis of the times used in basic procedures (i.e. nucleic acid extraction
and quality control along with sample acceptance and codification) suggests that their centrali-
zation, along with automation in shared work-units could help to implement efficiency and
reduce personnel costs for these processes. In addition, these could be shared between labora-
tories working on nucleic acids, including microbiology/virology and pathology labs.
Laboratory automation is also relevant for its impact on the global quality of results, as it
drastically reduces errors. In our study, we investigated the use of automated procedures for
both standard molecular biology techniques and NGS. Automated DNA extraction was used
by 69% of the laboratories. Conversely, in NGS procedures only one laboratory applied an
automated workflow for capture-based target enrichment, just 1/3 of laboratories use automa-
tion for amplicon-based target enrichment and just 3 laboratories use automated liquid han-
dling workstations for standard molecular biology procedures. We found that automated
DNA extraction requires much shorter times, as expected. A similar tendency can be observed
Fig 5. Hands-on times for NGS strategies. Hands-on times for NGS strategies. Panel A and B: amplicon- (A) and capture- (B) based technologies, considering library
preparation, run set-up and raw data processing. Panel C: data interpretation. In box plots, center lines show the medians; box limits indicate the 25th and 75th
percentiles as determined by R software; whiskers extend 1.5 times the interquartile range from the 25th and 75th percentiles, outliers are represented by dots.
https://doi.org/10.1371/journal.pone.0206855.g005
Laboratory hands-on-time in molecular diagnostics
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for standard molecular biology procedures and for NGS library preparation, although the
number of responding laboratories is too low to draw definite conclusions. These data support
again the need to centralize these procedures in order to optimize scale economy and operator
related timing.
However, in order to globally improve laboratory automation and management, more
efforts should be undertaken also by tech companies to adapt molecular genetics/genomics
equipment to management engineering standards that are appropriate to other types of labs.
Most of the instrumentation (especially those for NGS) cannot be interfaced with laboratory
management systems (LIMS), thus still precluding the implementation of a complete automa-
tion process.
A result that deserves a possible further analysis comes from the percentages of use of each
single molecular method. Virtually all laboratories perform, as expected, basic techniques.
Interestingly, Sanger sequencing is performed by the 84.6% of responding laboratories (Fig 1)
This shows on one hand that despite the fact that NGS is gaining ever-wider spaces in molecu-
lar diagnostics, Sanger sequencing still remains a key technology in molecular testing. Many
are the reasons why this occurs. Indeed, some clinically well-defined conditions still require
the targeted analysis (single gene diagnosis) of very limited portion of DNA sequence (i.e
hemoglobinopathies/thalassemias or connexin-26-related hearing loss characterization) These
are frequent Mendelian diseases due to mutations in small genes easily diagnosed by direct
sequencing. In addition, Sanger is still appropriate for mutation screening in families where
the genetic defect is known. Noteworthy, almost all guidelines for clinical NGS still require the
Sanger validation of pathological variants.
Finally, prenatal diagnosis of Mendelian conditions is largely based on Sanger sequencing
since causative mutations are already known but also when an urgent, not postponed, prenatal
testing is needed (late pregnancy testing). As soon as noninvasive prenatal testing (NIPT) will
be completely set up also for known Mendelian diseases, the usage of Sanger methods will be
probably, at least for prenatal testing, reduced. It should be however underlined that the 15.6%
of responding laboratories in our survey do not perform Sanger sequencing.
As far as the NGS is concerned, the survey shows that small gene panels are the main NGS
approach for the investigation of genetic diseases. Recent analyses show an advantage in cost
and in diagnostic power of whole genome sequencing (WGS) [9]and/or whole exome
sequencing (WES) [10]compared to targeted sequencing using small gene panels. Despite the
low number of responding laboratories, our results on WES analyses show that, as expected,
working times are considerably higher compared to panel testing, mainly, though not only,
due to longer times required for variant interpretation.
Indeed, our data show that, for all NGS strategies, the most time-consuming step in the
NGS analysis workflow is variant interpretation. The costs of sequencing are decreasing very
rapidly, faster than Moore’s law (Wetterstrand K. DNA sequencing costs: data from the
NHGRI large-scale genome sequencing program. http://www.genome.gov/sequencingcosts/).
Conversely, manpower costs of downstream result analysis and interpretation requiring spe-
cialist knowledge is definitely increasing and represents a major challenge for the future of
clinical genomics.
Although standards and guidelines for genetic test interpretation have been published in
2015[11], among the more than 7 million variants identified by the Exome Aggregation Con-
sortium (ExAC)[12], less than 300,000 unique interpreted variants have been submitted to
ClinVar by more than 630 laboratories, and one-third of these were classified by submitters as
variants of uncertain significance. Some very interesting approaches have been proposed to
support collaborative databases that systematically share genotype-phenotype correlations and
variant interpretation data [13–18].
Laboratory hands-on-time in molecular diagnostics
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In this regard, the European Union funded the RD-Connect project (www.rd-connect.eu).
This project is devoted to rare disease data collection and sharing including the NGS data in a
unique large repository where data submission and storage may facilitate genome/exome com-
parison for diagnostic settings and test interpretation. Similarly, NIH in USA has launched a
large collaborative action on rare diseases (RaDaR) with very similar purpose (https://ncats.
nih.gov/radar)Finally, we found that there is wide variation in workloads (samples per month)
for NGS analyses, with many laboratories processing low numbers of samples. This is in accor-
dance with the very high number of genetic services and laboratories in some countries,
including Italy, that also have an unequal distribution, with respect to the population size, as
described for Italy by Giardino et al.(6) Although this might be understandable in view of the
cultural and scientific background, some very rare diseases do need, it may have a negative
impact on the optimization of analytical processes and costs. The European Union has recently
approved the European Reference Networks (ERNs) for rare diseases (https://ec.europa.eu/
health/ern_en). These ERNs now already established for 24 rare disease Networks and have
the mission to harmonize the diagnosis and care of rare disorders, including genetic testing,
across Europe. Wide discussion is ongoing within the ERNs about the possibility to optimize
the molecular diagnosis of rare diseases in Reference centers that have a higher sample flow,
together with excellent cultural knowledge about the rare disease(s). This is believed to opti-
mize both analytical processes and their costs as well as a homogenous diagnostic offer for
Rare Patients across Europe. The ERN participating centers (or Health Care Providers or
HCPs), selected among various Excellence institutions in EU countries, are now entitled to
design the best network profile in order to provide a comprehensive, equal and update stan-
dard of care and diagnosis, and new personalized therapies to all patients and families with
rare genetic diseases. Nevertheless, this task is based on both Europe and Member States coop-
eration, but it also involves the entire Rare Disease community worldwide. Indeed, a stimulat-
ing challenge for the future of medical genetics.
In conclusion, we report as first a detailed workload calculation for the molecular genetics
diagnosis activities via a survey in Italian laboratories. These estimations may serve to better
evaluate the personnel effort need to optimize the molecular workflow, moving, when possible,
toward high automation. These values may also have a significant impact in setting up person-
nel recruitment strategies by Hospitals. Costs represent a crucial issue to be faced in the Health
care and are of outmost importance today, when the new NGS strategies have an increasing
role and a consequent economic impact in the medical field.
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S1 Fig. Hands-on times for standard PCR and the Sanger sequencing for increasing sample
volumes. In box plots, center lines show the medians; box limits indicate the 25th and 75th
percentiles as determined by R software; whiskers extend 1.5 times the interquartile range
from the 25th and 75th percentiles, outliers are represented by dots.
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